Linked Life Data

20224289

Source:http://linkedlifedata.com/resource/pubmed/id/20224289

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2010-4-14
pubmed:abstractText
Treatment of early Parkinson's disease (PD) should pursue objectives like possible disease-modifying effect, more physiological dopaminergic stimulation, and avoidance of motor fluctuations. The recent published ADAGIO trial showed that rasagiline (1 mg/day), used in early PD, has a disease-modifying effect. Dopaminergic drugs administered to provide more continuous dopaminergic stimulation prevent or minimize motor fluctuations in experimental animals. Dopamine (DA) agonists delay motor fluctuations in humans providing a more continuous dopaminergic stimulation. New formulations of DA agonists, such as once a day preparations and patch technology, have been developed to provide a more continuous delivery of drug and consequently a more physiological stimulation. According to patient characteristics, treatment of PD should be started with rasagiline and/or with long-acting DA agonists.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1660-2862
pubmed:author
pubmed:copyrightInfo
Copyright 2010 S. Karger AG, Basel.
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
213-5
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.
pubmed:affiliation
Department of Neurology, Institute of Research and Medical Care IRCCS San Raffaele, Rome, Italy. fabrizio.stocchi@sanraffaele.it
pubmed:publicationType
Journal Article